Stay updated with breaking news from Nexcella Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10,...
Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in...
Successful completion supports expansion of its ongoing NEXICART-1 NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing...
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapse...
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab...